The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood
- PMID: 31347104
- PMCID: PMC6860461
- DOI: 10.1007/s40273-019-00825-1
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood
Abstract
Transparency in health economic decision modelling is important for engendering confidence in the models and in the reliability of model-based cost-effectiveness analyses. The Mount Hood Diabetes Challenge Network has taken a lead in promoting transparency through validation with biennial conferences in which diabetes modelling groups meet to compare simulated outcomes of pre-specified scenarios often based on the results of pivotal clinical trials. Model registration is a potential method for promoting transparency, while also reducing the duplication of effort. An important network initiative is the ongoing construction of a diabetes model registry (https://www.mthooddiabeteschallenge.com). Following the 2012 International Society for Pharmacoeconomics and Outcomes Research and the Society of Medical Decision Making (ISPOR-SMDM) guidelines, we recommend that modelling groups provide technical and non-technical documentation sufficient to enable model reproduction, but not necessarily provide the model code. We also request that modelling groups upload documentation on the methods and outcomes of validation efforts, and run reference case simulations so that model outcomes can be compared. In this paper, we discuss conflicting definitions of transparency in health economic modelling, and describe the ongoing development of a registry of economic models for diabetes through the Mount Hood Diabetes Challenge Network, its objectives and potential further developments, and highlight the challenges in its construction and maintenance. The support of key stakeholders such as decision-making bodies and journals is key to ensuring the success of this and other registries. In the absence of public funding, the development of a network of modellers is of huge value in enhancing transparency, whether through registries or other means.
Conflict of interest statement
MW acknowledges employment by the Swedish Institute for Health Economics, which created and owns the ECHO-T2DM model and provides consulting services for its use. PC acknowledges payments for workshops on diabetes simulation modelling held alongside Mount Hood meetings. The Universities of Oxford and Melbourne have received royalties for the UKPDS Outcomes Model. PM is the managing director of Health Economics and Outcomes Research Ltd. TF developed the AdViSHE tool. All other authors (SK, FB, AT-D, IS, MT, PZ, WY, SL, WH, WS, AG, JL, ML, and AJP) report no conflicts of interest.
Similar articles
-
Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge.Value Health. 2018 Jun;21(6):724-731. doi: 10.1016/j.jval.2018.02.002. Epub 2018 Apr 9. Value Health. 2018. PMID: 29909878 Free PMC article.
-
Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics.Pharmacoeconomics. 2019 Nov;37(11):1371-1381. doi: 10.1007/s40273-019-00836-y. Pharmacoeconomics. 2019. PMID: 31531833 Review.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.Value Health. 2009 Nov-Dec;12(8):1086-99. doi: 10.1111/j.1524-4733.2009.00605.x. Epub 2009 Sep 10. Value Health. 2009. PMID: 19744291
-
Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.Pharmacoeconomics. 2017 Jul;35(7):673-683. doi: 10.1007/s40273-017-0508-2. Pharmacoeconomics. 2017. PMID: 28456972 Review.
Cited by
-
Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States.Pharmacoeconomics. 2021 Jun;39(6):631-638. doi: 10.1007/s40273-021-01036-3. Epub 2021 May 13. Pharmacoeconomics. 2021. PMID: 33982198 Free PMC article.
-
Prediction of complications in health economic models of type 2 diabetes: a review of methods used.Acta Diabetol. 2023 Jul;60(7):861-879. doi: 10.1007/s00592-023-02045-8. Epub 2023 Mar 3. Acta Diabetol. 2023. PMID: 36867279 Free PMC article. Review.
-
Development of a pharmacoeconomic registry: an example using hormonal contraceptives.Health Econ Rev. 2021 Mar 20;11(1):10. doi: 10.1186/s13561-021-00309-z. Health Econ Rev. 2021. PMID: 33745016 Free PMC article.
-
Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data.Pharmacoeconomics. 2024 Sep;42(9):929-953. doi: 10.1007/s40273-024-01388-6. Epub 2024 Jun 21. Pharmacoeconomics. 2024. PMID: 38904911 Free PMC article.
-
Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network.Pharmacoeconomics. 2022 Oct;40(10):1005-1009. doi: 10.1007/s40273-022-01179-x. Epub 2022 Jul 30. Pharmacoeconomics. 2022. PMID: 35907178 No abstract available.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical